New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis.

Hou Y, Zhao J, Martin W, Kallianpur A, Chung MK, Jehi L, Sharifi N, Erzurum S, Eng C, Cheng F. · 2020

Read New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. by Hou Y, Zhao J, Martin W, Kallianpur A, Chung MK, Jehi L, Sharifi N, Erzurum S, Eng C, Cheng F. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7360473.txt.

Introduction

Hou and co-authors examine genes that may shape who gets severe COVID-19, in BMC Medicine. Two host genes, ACE2 and TMPRSS2, control the virus's entry into cells. The team searched DNA variants in both genes across roughly 81,000 human genomes from many populations.

They found variant patterns that differ by ancestry. One ACE2 variant, found in African and African-American genomes, may alter interactions tied to heart and lung conditions. Other variants in both genes were common in some groups and rare in others. The authors present the catalogue as a starting point for explaining why risk varies so sharply between people. Lab and patient studies must test which variants truly change outcomes.

Catalog record

CREATORHou Y, Zhao J, Martin W, Kallianpur A, Chung MK, Jehi L, Sharifi N, Erzurum S, Eng C, Cheng F.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE30 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7360473

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis By Yuan Hou, Junfei Zhao, William Martin, Asha Kallianpur, Mina K Chung, Lara Jehi, Nima Sharifi, Serpil Erzurum, Charis Eng, Feixiong Cheng Published in: BMC Medicine DOI: 10.1186/s12916-020-01673-z ABSTRACT Abstract Background Coronavirus Disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has now been confirmed worldwide. Yet, COVID-19 is strangely and tragically selective. Morbidity and mortality due to COVID19 rise dramatically with age and co-existing health conditions, including cancer and cardiovascular diseases. Human genetic factors may contribute to the extremely high transmissibility of SARS-CoV-2 and to the relentlessly progressive disease observed in a small but significant proportion of infected individuals, but these factors are largely unknown. Main body In this study, we investigated genetic susceptibility to COVID-19 by examining DNA polymorphisms in ACE2 and TMPRSS2 (two key host factors of SARS-CoV-2) from ~ 81,000 human genomes. We found unique genetic susceptibility across different populations in ACE2 and TMPRSS2. Specifically, ACE2 polymorphisms were found to be associated with cardiovascular and pulmonary conditions by altering the angiotensinogen-ACE2 interactions, such as p.Arg514Gly in the African/African-American population. Unique but prevalent polymorphisms (including p.Val160Met (rs12329760), an expression quantitative trait locus (eQTL)) in TMPRSS2, offer potential explanations for differential genetic susceptibility to COVID-19 as well as for risk factors, including those with cancer and the high-risk group of male patients. We further discussed that polymorphisms in ACE2 or TMPRSS2 could guide effective treatments (i.e., hydroxychloroquine and camostat) for COVID-19. Conclusion This study suggested that ACE2 or TMPRSS2 DNA polymorphisms were likely associated with genetic susceptibility of COVID-19, which calls for a human genetics initiative for fighting the COVID-19 pandemic. Keywords: Angiotensin-converting enzyme 2 (ACE2), Coronavirus, COVID-19, Genetic susceptibility, SARS-CoV-2, TMPRSS2 BACKGROUND Coronaviruses (CoVs), so named for their “crown-like” appearance by electron microscopy, are a large family of viruses that spread from animal hosts (e.g., bats, civet, cats) to humans, causing life-threatening respiratory diseases like Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) [1]. As of June 18, 2020, over 8.4 million cases and 450,000 deaths resulting from infection by a novel SARS coronavirus, SARS-CoV-2 (also termed Coronavirus Disease 2019 or COVID-19), have now been confirmed worldwide; furthermore, there have been more than 2.2 million confirmed cases and over 110,000 deaths due to the COVID-19 pandemic in the USA alone [2]. Unlike other CoVs, SARS-CoV-2 has had much larger global spread and has impacted more people than SARS-CoV-1 and MERS-CoV combined [1]. Morbidity and mortality due to COVID-19 rise dramatically with age and co-existing health conditions, including cancer and cardiovascular diseases, and while most infected individuals recover, even very young and otherwise healthy patients may unpredictably succumb to this disease [3]. These observations beg the question of how much of the variation in COVID-19 disease severity may be explained by genetic susceptibility. Human genetic factors may contribute to the extremely high transmissibility of SARS-CoV-2 and to the relentlessly progressive disease observed in a small but significant proportion of infected individuals; yet, these factors are largely unknown. Development of new preventive and/or therapeutic strategies for COVID-19 will be greatly facilitated by systematic identification of host genetic pathways and DNA polymorphisms (variants) which modulate the risk of infection and severe illness, including the overexuberant immune response to the virus that often portends a poor outcome. Not only has the COVID-19 pandemic had huge health and economic impacts in 188 countries/regions across the world, but the disease has also struck in different racial/ethnic subpopulations. Large genetic studies in populations of geographically diverse ancestry have demonstrated substantial genetic variation in protein-coding regions, with widely varying allele frequencies [4]. SARS-CoV-2 infection depends on the host cell factors angiotensin-converting enzyme 2 (ACE2) for entry into cells and the host transmembrane serine protease TMPRSS2 for SARS-CoV-2 spike (S) protein priming [5] (Fig. 1a). ACE2, encoded on the X-chromosome, catalyzes the conversion of angiotensin II to angiotensin-(1–7), which acts as a vasodilator and exerts important modulatory effects on the cardiovascular system. TMPRSS2 is a key gene in prostate cancer, as an associated translocation drives ETS-family oncogene expression in a large proportion of tumors [6]. The distribution of ACE2 expression has recently been investigated by single-cell RNA sequencing, and the expression of both ACE2 and TMPRSS2 are likely to dictate SARS-CoV-2 tissue tropism [7]. Clinical studies have reported that incidence and mortality rates are significantly different between male and female COVID-19 patients, and the disease is associated with pre-existing conditions, such as cancer and cardiovascular disorders, in particular individuals with hypertension receiving anti-hypertensive medications [8]. Therefore, a systematic investigation of the functional polymorphisms in ACE2 and TMPRSS2 among different populations could pave the way for precision medicine and personalized treatment strategies for COVID-19. [Figure: The coding-region variants in ACE2 and TMPRSS2 from ~ 81,000 human genomes across 8 populations. a Coding-region variants in the genes encoding angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2) across three human genome databases: (i) Genome Aggregation Database (gnomAD v3), (ii) Exome Sequencing Project (ESP), and (iii) 1000 Genomes Project (1KGP). SARS-CoV-2 utilizes the host cell factors angiotensin-converting enzyme 2 (ACE2) for entry into cells and the host transmembrane serine protease TMPRSS2 for SARS-CoV-2 spike (S) protein priming, offering potential pathway for therapeutic development in treatment of COVID-19. b Distribution of 61 deleterious variants in the ACE2 coding region identified in gnomAD (v3). Polyphen2 > 0.96 and CADD scores > 20 as cutoff identify putative deleterious variants. The upper panel using 3 colors shows the functional domains of ACE2, and the height of the vertical line represents the number of populations that carry this variant. The lower heatmap shows the allele frequencies (color key) of a variant across different populations. c Distributions of 63 putative deleterious variants in the TMPRSS2 coding region using the same approach of b. AFR, African/African-American; AMI, Amish; AMR, Latino/Admixed American; ASJ, Ashkenazi Jewish; EAS, East Asian; FIN, Finnish; EUR, Non-Finnish European; SAS, South Asian; PNA, population not assigned] ACE2 POLYMORPHISM ANALYSIS ACROSS DIFFERENT POPULATIONS Here, we investigated genetic susceptibility to COVID-19 by examining DNA polymorphisms in ACE2 (OMIM 300335) and TMPRSS2 (OMIM 602060) genes. We assembled a total of 437 non-synonymous single-nucleotide variants (SNVs) in the protein-coding regions of ACE2 and TMPRSS2 (Fig. 1a) from three databases: (i) Genome Aggregation Database (gnomAD v3: gnomad.broadinstitute.org, covering 9 geographical areas), (ii) Exome Sequencing Project (ESP: evs.gs.washington.edu/EVS/), and (iii) 1000 Genomes Project (1KGP, www.internationalgenome.org). We used ANNOVAR [9] to annotate all non-synonymous variants. By applying Polyphen2 and CADD (Combined Annotation Dependent Depletion) scores, we identified 63 potentially deleterious variants in ACE2 (61 in gnomAD) and 68 deleterious variants in TMPRSS2 (63 in gnomAD). We found that the distribution of deleterious variants in ACE2 differs among 9 populations in gnomAD (v3). Specifically, 39% (24/61) and 54% (33/61) of deleterious variants in ACE2 occur in African/African-American (AFR) and Non-Finnish European (EUR) populations, respectively (Fig. 1b). Prevalence of deleterious variants among Latino/Admixed American (AMR), East Asian (EAS), Finnish (FIN), and South Asian (SAS) populations is 2–10%, while Amish (AMI) and Ashkenazi Jewish (ASJ) populations do not appear to carry such variants in ACE2 coding regions (Fig. 1b). Specifically, several variants, including p.Met383Thr, p.Pro389His, and p.Asp427Tyr, have been reported to slightly

Read the complete text